Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12350704 | 0.88 | KCNK3 (0.58) | KCNK3KCNK9MEN1KMT2ACA1 | |
| SCHEMBL18343409 | 0.88 | KCNK3 (0.61) | KCNK3SMN1; SMN2HTTLMNAMEN1 | |
| SCHEMBL22290255 | 0.88 | NT5E (0.58) | KCNK3KCNK9HTTLMNAMEN1 | |
| SCHEMBL11987744 | 0.86 | CA1 (0.52) | KCNK3SMN1; SMN2KCNK9MEN1KMT2A | |
| SCHEMBL104107 | 0.84 | KCNK9 (0.60) | KCNK3SMN1; SMN2KCNK9HTTLMNA | |
| SCHEMBL18343198 | 0.83 | CSF1R (0.51) | KCNK3SMN1; SMN2KCNK9MEN1KMT2A | |
| SCHEMBL24628621 | 0.83 | MEN1 (0.50) | KCNK3KCNK9LMNAMEN1KMT2A | |
| SCHEMBL18343271 | 0.82 | MEN1 (0.49) | KCNK3SMN1; SMN2KCNK9HTTMEN1 | |
| SCHEMBL18343415 | 0.82 | MEN1 (0.50) | KCNK3SMN1; SMN2KCNK9HTTMEN1 | |
| SCHEMBL18343194 | 0.82 | BRAF (0.47) | HTTALDH1A1RAB9ANAMPTTYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988484-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988484-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190315772-A1 | GLUCOSE UPTAKE INHIBITORS | KADMON CORP LLC (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190315772-A1 | GLUCOSE UPTAKE INHIBITORS | KADMON CORP LLC (US) | 2019-10-17 | — | — | US | disclosed |
| US-10273248-B2 | Glucose uptake inhibitors | Kadmon Corportion, LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273248-B2 | Glucose uptake inhibitors | Kadmon Corportion, LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180298029-A1 | GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION LLC (US) | 2018-10-18 | — | — | US | disclosed |
| EP-3313825-A1 | GLUCOSE UPTAKE INHIBITORS | Kadmon Corporation, LLC (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016210330-A1 | GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION, LLC (US) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180298029-A1 | GLUCOSE UPTAKE INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | KCNK3 2205/4885SMN1; SMN2 4337/4885KCNK9 2340/4885 |
| US-10988484-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A2, SLC2A4 | KCNK3 2320/4885SMN1; SMN2 4406/4885KCNK9 2510/4885 |
| US-20190315772-A1 | GLUCOSE UPTAKE INHIBITORS | SLC2A1, SLC2A4, SLC2A2 | KCNK3 2861/4885SMN1; SMN2 4535/4885KCNK9 3026/4885 |
| US-10273248-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A2, SLC2A4 | KCNK3 2205/4885SMN1; SMN2 4337/4885KCNK9 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.